Cargando…
Patient perspectives on Peyronie’s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum
Intralesional injection of collagenase clostridium histolyticum (CCH) improves Peyronie’s disease (PD) symptoms; however, patient perspectives regarding PD and CCH treatment have not been fully elucidated. This cross-sectional qualitative study included heterosexual men with PD who received ≥1 injec...
Autores principales: | Kaminetsky, J., Gittelman, M., Kaufman, G. J., Smith, T. M., Jordan, G. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760640/ https://www.ncbi.nlm.nih.gov/pubmed/30237548 http://dx.doi.org/10.1038/s41443-018-0027-5 |
Ejemplares similares
-
Role of collagenase clostridium histolyticum in Peyronie’s disease
por: Peak, Taylor C, et al.
Publicado: (2015) -
Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease: patient selection and perspectives
por: Kuhlmann, Paige K, et al.
Publicado: (2017) -
Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie’s disease
por: Nguyen, Hoang Minh Tue, et al.
Publicado: (2017) -
Expanding the role of injectable collagenase clostridium histolyticum for the treatment of active phase Peyronie’s disease
por: Aliperti, Louis A., et al.
Publicado: (2017) -
The Impact of Clostridium Histolyticum Collagenase on the Prevalence and Management of Peyronie's Disease in the United States
por: Sun, Andrew J., et al.
Publicado: (2019)